ASMPT(00522.HK)去年少賺17% 股價仍升4.6%
ASMPT(00522.HK)今日高開2.24%,最高見70元。現報70元,升4.63%,成交54.07萬股,涉資3,712.35萬元。
ASMPT去年少賺17%至26.2億美元,派末期息每股1.9元,收入跌12%至193.63億元,但仍創下集團年度銷售收入第二新高紀錄。
高盛發表報告,ASMPT去年第四季收入(按季跌5%)、毛利率(按季升0.5個百點)及營運盈利優於預期,指公司對2023年首季收入指引亦符合該行預期,指ASMPT盈利向復甦推進,料2023年盈利可按年跌29%,估2024年盈利可按年升40%,重申對其「買入」評級及目標價81元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.